Source: International Congress 2017 – Novel and old entities
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Wiertz (Utrecht, Netherlands). Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease. 3828

Member's Comments

No comment yet.

Related content which might interest you: Rituximab for the treatment of chronic hypersensitivity pneumonitis Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia Source: Eur Respir J 2005; 25: 528-533 Year: 2005 Chronic hypersensitivity pneumonitis with familial history of interstitial lung disease Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Hypersensitivity pneumonitis associated with the use of temozolomide Source: Eur Respir J 2009; 33: 931-934 Year: 2009 Ciprofloxacin-induced acute interstitial pneumonitis Source: Eur Respir J 2004; 23: 172-174 Year: 2004 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Cyclosporine A in the treatment of idiopathic pulmonary fibrosis/usual interstitial pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 62s Year: 2002 Interstitial pneumonia vs. hypersensitivity pneumonitis with autoimmune features Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Comparison of the clinical features of lung cancer in chronic hypersensitivity pneumonitis (CHP) and in collagen vascular disease related interstitial pneumonitis (CVD-IP) Source: Eur Respir J 2006; 28: Suppl. 50, 675s Year: 2006 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Cyclophosphamide in steroid refractory unclassifiable idiopathic interstitial pneumonia and interstitial pneumonia with autoimmune features (IPAF) Source: Eur Respir J, 51 (4) 1702519; 10.1183/13993003.02519-2017 Year: 2018 Chronic hypersensitivity pneumonitis and its differential diagnosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 978-1-904097-51-8, page=189 Year: 2007 Chronic interstitial pneumonitis in end-stage sarcoidosis Source: Eur Respir J 2010; 35: 695-697 Year: 2010 Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Tacrolimus for antisynthetase syndrome with interstitial lung disease? Source: Eur Respir J 2008; 32: 244-245 Year: 2008 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Distinguishing fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis Source: International Congress 2019 – Lungs in the fog Year: 2019 Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013